Is it acceptable to give weekly cisplatin for patients with locally advanced head and neck SCC undergoing chemoradiation?
Is there data to support every 3 week dosage v. weekly?
| https://ascopost.com/news/march-2022/postoperative-weekly-vs-every-3-week-cisplatin-in-chemoradiation-for-locally-advanced-head-and-neck-cancer/ |
Answer from: Radiation Oncologist at Academic Institution
@Nabil F. Saba just presented at the ASCO H&N highlights session that weekly cisplatin 40mg/m2 is now considered a standard of care, at least in the post-op high risk setting based on data by Dr. Kiyota et al. showing superior outcomes, likely due to higher cumulative cisplatin dose (>200mg/m...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
A number of chemotherapeutic agents have been utilized as radiation sensitizers during concomitant therapy. However, the most commonly used regimens include high-dose cisplatin (100 mg/m2 every 21 days for two or three doses), weekly cisplatin (30-40 mg/m2), weekly carboplatin (AUC=2) plus paclitaxe...
Answer from: Medical Oncologist at Academic Institution
Recently published data suggests that weekly cisplatin 30 mg/m2 is inferior to high dose cisplatin (1). In a randomized phase III trial comparing high dose cisplatin at 100 mg/m2 to weekly cisplatin, weekly cisplatin resulted in a significantly higher risk of locoregional recurrence and a trend tow...